CuralysMD™ has been evaluated in two randomized, double-blind, vehicle-controlled clinical studies — one in adults and one in pediatric patients with mild-to-moderate atopic dermatitis (AD).
CuralysMD™ has been evaluated in two randomized, double-blind, vehicle-controlled clinical studies — one in adults and one in pediatric patients with mild-to-moderate atopic dermatitis (AD).
These insights validate the unique ability of SMRTActiv™ Technology with colloidal oatmeal, to treat the root causes of atopic dermatitis — not just its symptoms.
| Clinical Study Results: | ||
|---|---|---|
| PARAMETERS | ADULTS | PEDIATRICS (2–17 YRS OLD) |
| Skin Clearance | ✓ | ✓ |
| Itch Reduction | ✓ | ✓ |
| Reduce Topical Steroid use | ✓ | ✓ |
| Reduce S. aureus on skin | ✓ | ✓ |
No treatment-related adverse events were reported in either trial. The formulation was well-tolerated across age groups and compatible with standard topical therapies.